Paper Report for: Chen_2016_Onco.Targets.Ther_9_1151
Reference
Title: Association between L55M polymorphism in Paraoxonase 1 and cancer risk: a meta-analysis based on 21 studies Chen L, Lu W, Fang L, Xiong H, Wu X, Zhang M, Wu S, Yu D Ref: Onco Targets Ther, 9:1151, 2016 : PubMed
L55M polymorphism in Paraoxonase 1 (PON1) has been regarded as a risk factor for many cancer types. Nevertheless, the results remain controversial and inconclusive. We therefore performed a meta-analysis of all eligible case-control studies to evaluate the association between L55M polymorphism and cancer risk. Odds ratios (ORs) with 95% confidence intervals (CIs) were used to assess the strength of the associations. Finally, a total of 5,627 cases and 6,390 controls, arising from 21 case-control studies, were enrolled in our study. Significant associations between PON1-L55M polymorphism and overall cancer risk were identified in all genetic models. In the stratified analyses by cancer type, PON1-L55M polymorphism was a risk factor for breast cancer in all genetic models, prostate cancer in the heterozygote model (ML vs LL: OR =1.304, 95% CI =1.049-1.620, P heterogeneity=0.067), and ovarian cancer in the recessive model (MM vs ML/LL: OR =1.526, 95% CI =1.110-2.097, P heterogeneity=0.464). Similarly, an increased risk was also identified for the Caucasian population in the heterozygote comparison and homozygote models, and hospital-based controls in all genetic models. To sum up, our study suggests that the PON1-L55M allele increased the risk of cancer. Future well-designed studies with larger sample sizes are warranted to further verify these findings.
        
Related information
Citations formats
Chen L, Lu W, Fang L, Xiong H, Wu X, Zhang M, Wu S, Yu D (2016) Association between L55M polymorphism in Paraoxonase 1 and cancer risk: a meta-analysis based on 21 studies Onco Targets Ther9: 1151-8
Chen L, Lu W, Fang L, Xiong H, Wu X, Zhang M, Wu S, Yu D (2016) Onco Targets Ther9: 1151-8